Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Developmen...(in July the enrollment of the 20th hemat...),Health

cell transplant recipient in the company's Phase 2 trial of a DNA

vaccine against cytomegalovirus (CMV). After the 20th recipient's

two-month follow-up visit, an independent data safety monitoring board

will conduct an interim evaluation of safety data for all subjects

enrolled in the trial.

-- The company has initiated 30 of up to 60 planned clinical sites for the

AIMM (Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma) Phase

3 pivotal trial of the Allovectin-7(R) cancer immunotherapeutic as

first-line therapy in chemotherapy-nave patients with recurrent Stage

III or IV metastatic melanoma. The trial is being funded by AnGes under

a collaborative agreement with Vical.

-- During the second quarter, the company completed the final contract

manufacturing and shipment of HIV vaccine bulk DNA under a $12 million

production order for the National Institutes of Health (NIH) for a

planned Phase 2b efficacy proof-of-concept trial expected to begin this

year with the support of the Partnership for AIDS Vaccine Evaluation

(PAVE). The PAVE trial will test a vaccine regimen combining a DNA

prime based on Vical's technology with an adenoviral vector boost in up

to 8,500 volunteers at sites in the United States, Africa, the

Caribbean and South America to determine its potential to prevent

infection or disease progression.

-- Vical was awarded a three-year, $6.0 million grant from the National

Institute of Allergy and Infectious Diseases (NIAID), part of the NIH,

for further development of a DNA vaccine manufacturing process with the

potential to produce several million doses of vaccines in a matter of

days. By using a cell-free manufacturing process, the company believes

that the RapidR
'/>"/>

SOURCE Vical Copyright©2007 PR Newswire.

0 GOOD